Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder with Modafinil

用莫达非尼治疗双相情感障碍的昼夜节律和认知功能障碍

基本信息

项目摘要

DESCRIPTION (provided by applicant): Despite advances in the treatment of bipolar disorder, most patients do not achieve complete inter-episode recovery and functional disability is common. During periods of relative remission, many patients continue to experience sleep disturbances, reduced daytime activity levels, and neurocognitive dysfunction. These persistent features of the illness represent critical treatment targets, as they do not adequately improve with standard mood stabilizing medications and they are strongly associated with functional disability and poor quality of life. Psychosocial therapies have focused on the importance of stabilizing sleep-wake cycles and daily routines such as mealtimes and regular social interactions, resulting in significant reductions in affective relapse. No study, to date, has attempted to stabilize circadian rhythms using a pharmacologic intervention in bipolar patients. Thus, the proposed 8-week, randomized, placebo-controlled pilot study will evaluate the safety and preliminarily assess the efficacy of the wake-promoting drug, modafinil (Provigil(R)), on sleep, daytime activity, and neurocognitive functioning in 48 euthymic bipolar patients. Modafinil is approved by the US Food and Drug Administration (FDA) for excessive daytime sleepiness associated with several sleep disorders (narcolepsy, sleep apnea, and shift-work disorder). In an off-label application, we will administer randomize in a 2:1 ratio to active modafinil (200mg/day) or placebo to 48 affectively stable patients with bipolar I disorder for 8 weeks. We will measure patients' subjective experience of sleep disruption and daytime wakefulness by questionnaires and daily diaries. In addition, we will focus on modafinil's potential to improve neurocognitive functioning, including attention, memory and higher order cognitive processes in patients with bipolar disorder, as it has previously been shown to enhance cognition in psychiatrically healthy individuals, patients with sleep disorders, and patients with schizophrenia. To measure cognitive functioning, we will deploy several paper-pencil and computerized tests before modafinil is administered and again at the end of the 8-week study. Finally, although not a primary focus of the current study, we will also investigate the effects of modafinil on low-grade depressive symptoms independent of sleep ratings, regularity of social rhythms, and patient-reported quality of life. We will closely monitor patiets for unforeseen changes in mood symptoms that are deemed to place them at risk for developing mania or depression and will discontinue the trial as deemed necessary. We expect that findings from this study will identify a novel approach for treating those persistent symptoms of bipolar disorder not adequately addressed with current mood stabilizing agents, potentially resulting in a more complete recovery and improvement in day-to-day functioning.
描述(由申请人提供):尽管双相情感障碍的治疗取得了进展,但大多数患者无法实现完全的发作间恢复,功能障碍很常见。在相对缓解期间,许多患者继续经历睡眠障碍、日间活动水平降低和神经认知功能障碍。这些疾病的持续特征代表了关键的治疗目标,因为它们不能用标准的情绪稳定药物充分改善,并且它们与功能障碍和生活质量差密切相关。心理社会疗法的重点是稳定睡眠-觉醒周期和日常生活的重要性,如进餐时间和定期的社交互动,从而显着减少情感复发。到目前为止,还没有研究试图通过药物干预来稳定双相情感障碍患者的昼夜节律。因此,这项拟议的为期8周、随机、安慰剂对照的初探性研究将评估促醒药物莫达非尼(Provigil(R))对48名心境正常的双相情感障碍患者的睡眠、日间活动和神经认知功能的安全性并初步评估其疗效。 莫达非尼被美国食品和药物管理局(FDA)批准用于与几种睡眠障碍(发作性睡病,睡眠呼吸暂停和轮班工作障碍)相关的日间过度嗜睡。在标签外应用中,我们将以2:1的比例随机给予48名情感稳定的双相I型障碍患者活性莫达非尼(200 mg/天)或安慰剂8周。我们将通过问卷调查和每日日记来测量患者对睡眠中断和白天觉醒的主观体验。此外,我们将重点关注莫达非尼改善神经认知功能的潜力,包括双相情感障碍患者的注意力,记忆力和高阶认知过程,因为它以前已被证明可以增强精神健康个体,睡眠障碍患者和精神分裂症患者的认知。为了测量认知功能,我们将在莫达非尼给药前和8周研究结束时进行几次纸笔和计算机测试。最后,虽然不是当前研究的主要焦点,但我们还将研究莫达非尼对独立于睡眠评级、社交节律规律性和患者报告的生活质量的轻度抑郁症状的影响。 我们将密切监测患者情绪症状的不可预见的变化,这些变化被认为是使他们处于发展躁狂或抑郁的风险中,并将在必要时停止试验。我们希望这项研究的结果将确定一种新的方法来治疗那些目前情绪稳定剂未充分解决的双相情感障碍的持续症状,可能导致更完全的恢复和日常功能的改善。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Katherine Elizabeth Burdick其他文献

Katherine Elizabeth Burdick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Katherine Elizabeth Burdick', 18)}}的其他基金

Using allopregnanolone to probe behavioral and neurobiological mechanisms that underlie depression in women across perimenopausal stage
使用四氢孕酮探讨围绝经期女性抑郁症的行为和神经生物学机制
  • 批准号:
    10557128
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
Using allopregnanolone to probe behavioral and neurobiological mechanisms that underlie depression in women across perimenopausal stage
使用四氢孕酮探讨围绝经期女性抑郁症的行为和神经生物学机制
  • 批准号:
    10358658
  • 财政年份:
    2022
  • 资助金额:
    $ 25.43万
  • 项目类别:
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
衰老和情绪障碍中基于大脑的情绪调节机制
  • 批准号:
    10319173
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
衰老和情绪障碍中基于大脑的情绪调节机制
  • 批准号:
    10154000
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
衰老和情绪障碍中基于大脑的情绪调节机制
  • 批准号:
    10514586
  • 财政年份:
    2020
  • 资助金额:
    $ 25.43万
  • 项目类别:
Understanding the neurocognitive heterogeneity in bipolar disorder
了解双相情感障碍的神经认知异质性
  • 批准号:
    9493978
  • 财政年份:
    2017
  • 资助金额:
    $ 25.43万
  • 项目类别:
Neurocognitive Heterogeneity in Patients with Psychosis _ A Dimensional Approach
精神病患者的神经认知异质性_维度方法
  • 批准号:
    8828502
  • 财政年份:
    2014
  • 资助金额:
    $ 25.43万
  • 项目类别:
1/2-Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)
1/2-普拉克索治疗双相情感障碍:目标认知 (PRAM-BD)
  • 批准号:
    8760643
  • 财政年份:
    2014
  • 资助金额:
    $ 25.43万
  • 项目类别:
1/2-Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)
1/2-普拉克索治疗双相情感障碍:目标认知 (PRAM-BD)
  • 批准号:
    9070766
  • 财政年份:
    2014
  • 资助金额:
    $ 25.43万
  • 项目类别:
Neurocognitive Heterogeneity in Patients with Psychosis _ A Dimensional Approach
精神病患者的神经认知异质性_维度方法
  • 批准号:
    8634973
  • 财政年份:
    2014
  • 资助金额:
    $ 25.43万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.43万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了